Strengthening the Digital Pathology Business Segment
First written in FY2022-Q2. 9 of 12 entries say "Advanced", first in FY2022-Q3. Latest entry: FY2026.
0 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「The “E1000 Dx digital pathology solution” received marketing approval in Japan as a Class II controlled medical device and went on sale on 16 April 2026.」
Following 510(k) clearance from the U.S. FDA, the product received marketing approval in Japan as a Class II controlled medical device, advancing to the launch stage. - FY2026-H1AdvancedAnnual report
「Excluding foreign exchange effects, pathology business revenue was in line with the previous corresponding period. Revenue declined in the Americas due to the ongoing impact of sluggish demand for instruments, but increased in Europe, where sales of glass products and consumables remained solid and a large digital pathology product order was secured in the first quarter of the current consolidated fiscal period, and in the Asia-Pacific region, where revenue grew as the product portfolio of locally manufactured products was expanded, including the start of digital pathology product manufacturing in China.」
The company progressed in expanding its product portfolio, including local production, by securing a large digital pathology order and beginning digital pathology product manufacturing in China. - FY2025AdvancedAnnual report
「The E1000 Dx digital pathology solution received 510(k) clearance from the U.S. FDA. E1000 Dx comprises an automated high-speed whole-slide imaging digital scanner, a medical monitor, and advanced image management and viewing software, and can create high-resolution digital images of up to 1,500 tissue samples per day.」
The E1000 Dx digital pathology solution received 510(k) clearance from the U.S. FDA, advancing its commercialization and regulatory process. - FY2024AdvancedAnnual report
「The company began selling in Japan the “PANNORAMIC 480” digital slide scanner developed by 3DHistech Ltd.」
In digital pathology, the company began selling slide scanners in Japan and slide printers in the United States. Development of digital pathology and immunohistochemistry technologies also continued. - FY2024-Q3RestatedAnnual report
「The increase in pathology business revenue was mainly attributable to favorable foreign exchange effects, the impact of product shortages caused by COVID-19 during the first quarter of the previous fiscal year, the effects of M&A conducted in July last year, and product price revisions, among other factors. By region, revenue increased in all regions, partly due to favorable foreign exchange effects.」
The pathology business posted higher revenue due to the effects of the M&A conducted in July last year and product price revisions, with revenue increasing in all regions. - FY2024-Q2RestatedAnnual report
「The increase in pathology business revenue was mainly attributable to favorable foreign exchange effects, the impact of M&A conducted in July last year, and the effects of product price revisions, among other factors.」
In the pathology business, revenue increased 10.3% year on year, supported by the effects of existing M&A, product price revisions and favorable foreign exchange effects. - FY2024-Q1AdvancedAnnual report
「Revenue in the pathology business was ¥12,428 million, up 23.4% year on year. Revenue increased year on year, mainly because instrument sales rose in Europe and the Asia-Pacific region compared with the previous corresponding period, which was affected by product shortages caused by COVID-19-related lockdowns in China, in addition to favorable foreign exchange effects, the impact of M&A and the effects of product price revisions.」
Revenue in the pathology business increased 23.4% year on year, driven by the effects of M&A, product price revisions, and higher instrument sales in Europe and the Asia-Pacific region. - FY2023-Q3AdvancedAnnual report
「Revenue in the pathology business increased despite lower sales of instruments and slides year on year, supported by favorable foreign exchange effects, higher revenue from M&A, and strong sales of digital pathology products and consumables.」
The company cited higher revenue from M&A and strong digital pathology sales, explaining that the strengthening of the pathology diagnostics business led to higher revenue. - FY2023-Q2AdvancedAnnual report
「The number of affiliated companies increased by 2. In the diagnostics and life sciences segment, this reflected an increase of 2 consolidated subsidiaries and 1 jointly controlled operation to strengthen the pathology diagnostics business, offset by a decrease of 1 consolidated subsidiary in the diabetes management segment due to the reorganization of sales sites.」
Strengthening the pathology diagnostics business increased the number of consolidated subsidiaries by 2 and jointly controlled operations by 1, while the reorganization of diabetes management sales sites reduced the number by 1, resulting in a net increase of 2 affiliated companies. - FY2023-Q1AdvancedAnnual report
「In the diagnostics and life sciences segment, the number of consolidated subsidiaries increased by 2 among the company's affiliated companies. This was to strengthen the pathology diagnostics business.」
The number of consolidated subsidiaries increased by 2 to strengthen the pathology diagnostics business. - FY2022-Q3AdvancedAnnual report
「In the diagnostics and life sciences segment, the number of affiliated companies increased by 3. This resulted from an increase of 4 affiliated companies to strengthen the pathology diagnostics business, offset by a decrease of 1 company following the integration of pathology business sales sites.」
The number of affiliated companies increased by 4 to strengthen the pathology diagnostics business, while 1 company was reduced through the integration of sales sites, resulting in a net increase of 3 companies. - FY2022-Q2First statedAnnual report
「In the diagnostics and life sciences segment, the number of affiliated companies increased by 2 as part of efforts to strengthen the digital pathology business within the pathology diagnostic process.」
The company stated that the number of affiliated companies increased by 2 to strengthen the digital pathology business.